(Q41708449)

7 October 2017

1 reference

title

High-dose therapy with fluconazole > or = 800 mg day-1. (English)

1 reference

7 October 2017

1 reference

Duswald KH

1

1 reference

7 October 2017

Penk A

series ordinal

2

1 reference

7 October 2017

Pittrow L

series ordinal

3

1 reference

7 October 2017

publication date

1 November 1997

1 reference

7 October 2017

1 reference

7 October 2017

volume

40

1 reference

7 October 2017

issue

7-8

1 reference

7 October 2017

page(s)

267-277

1 reference

Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality

7 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00231.X

Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00231.X

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00231.X

Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00231.X

Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00231.X

Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00231.X

Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00231.X

High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. The California Collaborative Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00231.X

High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00231.X

Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00231.X

Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00231.X

Alopecia associated with fluconazole therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00231.X

Coccidioidomycosis: new aspects of epidemiology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00231.X

Fluconazole in the treatment of candidiasis in immunocompromised children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00231.X

Therapy for cryptococcal meningitis in patients with AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00231.X

Therapy for fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00231.X

Role of azoles in antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.1997.TB00231.X

10.1111/J.1439-0507.1997.TB00231.X

21 January 2018

Identifiers

DOI

1 reference

7 October 2017

1 reference